Adhansia XR (methylphenidate HCI)
Title: Adhansia XR (methylphenidate HCI)Category: MedicationsCreated: 7/8/2021 12:00:00 AMLast Editorial Review: 7/8/2021 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 8, 2021 Category: Drugs & Pharmacology Source Type: news
New Obesity Target? Dopamine Circuit in Brainstem Affects Satiety New Obesity Target? Dopamine Circuit in Brainstem Affects Satiety
A newly identified dopaminergic neural circuit in the hindbrain plays a role in satiety, a mouse study found, which methylphenidate, approved for ADHD, but which also causes appetite loss, acts on.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 4, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Drug Holiday? Benefits, Risk to Kids With ADHD Drug Holiday? Benefits, Risk to Kids With ADHD
Letting children with ADHD take a weekend or summer break from methylphenidate may lead to several benefits, but experts urge caution when doing so.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 13, 2021 Category: Consumer Health News Tags: Psychiatry News Source Type: news
Use of methylphenidate and the incidence of intentional self-harm or suicide attempts among individuals with schizophrenia, bipolar disorder and personality disorder - Rohde C, Salagre E, Nielsen J, Østergaard SD.
[Abstract unavailable]
Language: en... (Source: SafetyLit)
Source: SafetyLit - March 4, 2021 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Adhansia XR (Methylphenidate Hydrochloride Extended-release Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 17, 2021 Category: Drugs & Pharmacology Source Type: news
Students' stimulant use for cognitive enhancement: a deliberate choice rather than an emotional response to a given situation - Ponnet K, Tholen R, De Bruyn S, Wouters E, Van Ouytsel J, Walrave M, Van Hal G.
BACKGROUND: Prescription stimulants such as methylphenidate are usually prescribed to treat attention deficit (and hyperactivity) disorders (ADHD). Recently, these drugs have gained popularity among college students, because of the belief that they can hel... (Source: SafetyLit)
Source: SafetyLit - December 3, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Dr Reddy's launches generic attention deficit disorder drug in US market
New Delhi, Sep 3 () Dr Reddy's Laboratories on Thursday said it has launched Methylphenidate Hydrochloride extended-release tablets, used to treat attention deficit disorder (ADD), in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 2, 2020 Category: Pharmaceuticals Source Type: news
Methylphenidate and the risk of burn injury among children with attention-deficit/hyperactivity disorder - Chen VCH, Yang YH, Yu Kuo T, Lu ML, Tseng WT, Hou TY, Yeh JY, Lee CTC, Chen YL, Lee MJ, Dewey ME, Gossop M.
AIMS: Attention-deficit/hyperactivity disorder (ADHD) is associated with a higher risk of burn injury than in the normal population. Nevertheless, the influence of methylphenidate (MPH) on the risk of burn injury remains unclear. This retrospective cohort ... (Source: SafetyLit)
Source: SafetyLit - July 23, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Methylphenidate and mortality in children with attention-deficit hyperactivity disorder: population-based cohort study - Chen VCH, Chan HL, Wu SI, Lu ML, Dewey ME, Stewart R, Lee CTC.
BACKGROUND: Little is known about methylphenidate (MPH) use and mortality outcomes.
AIMS: To investigate the association between MPH use and mortality among children with an attention-deficit hyperactivity disorder (ADHD) diagnosis.
METHOD: This po... (Source: SafetyLit)
Source: SafetyLit - July 17, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work
Stimulants such as methylphenidate are increasingly used for cognitive enhancement but precise mechanisms are unknown. We found that methylphenidate boosts willingness to expend cognitive effort by altering the benefit-to-cost ratio of cognitive work. Willingness to expend effort was greater for participants with higher striatal dopamine synthesis capacity, whereas methylphenidate and sulpiride, a selective D2 receptor antagonist, increased cognitive motivation more for participants with lower synthesis capacity. A sequential sampling model informed by momentary gaze revealed that decisions to expend effort are related to ...
Source: ScienceNOW - March 18, 2020 Category: Science Authors: Westbrook, A., van den Bosch, R., Määttä, J. I., Hofmans, L., Papadopetraki, D., Cools, R., Frank, M. J. Tags: Neuroscience, Psychology reports Source Type: news
Association of methylphenidate use and traditional/cyberbullying - Tural Hesapcioglu S, Kandemir G.
This study aims to determine whether there is a difference in terms of traditional/cyberbullying or victimization among adolescents receiving methylphenidate for attention deficit hyperactivity disorder (ADHD) and treatment-na ïve adolescents w... (Source: SafetyLit)
Source: SafetyLit - February 8, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
The effects of methylphenidate on stress fractures in patients age 10-29: a national database study - DeFroda SF, Quinn M, Yang DS, Daniels AH, Owens BD.
This study further investigates this effect utilizing a large na... (Source: SafetyLit)
Source: SafetyLit - February 7, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Rich rewards: Scientists reveal ADHD medication's effect on the brain
(Okinawa Institute of Science and Technology (OIST) Graduate University) Researchers at the Okinawa Institute of Science and Technology Graduate University (OIST) have identified how certain areas of the human brain respond to methylphenidate -- a stimulant drug which is used to treat symptoms of ADHD. The work may help researchers understand the precise mechanism of the drug and ultimately develop more targeted medicines for the condition. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 17, 2020 Category: Biology Source Type: news
Medicines Supply Communications
Delmosart (methylphenidate) 18mg prolonged-release tablets
The Department of Health and Social Care (DHSC) has issued a Medicine Supply Notification for Delmosart (methylphenidate) 18mg prolonged-rel (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - November 1, 2019 Category: Drugs & Pharmacology Source Type: news
